Vasoserc

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vasoserc

Property Description
Active ingredient Betahistine dihydrochloride
Form Oral tablet or oral solution
Pharmacological class Anti-vertigo agent; Vestibular system modulator
Common use Alleviating symptoms of dizziness and vertigo
Origin Synthetic compound (Histamine analogue)

What Type of Medicine is Vasoserc?

Vasoserc is a medication containing the active compound Betahistine, which is classified as a synthetic histamine analogue and an anti-vertigo agent. The substance is structurally similar to the naturally occurring substance histamine, which enables it to modulate the balance signals within the inner ear and brain. The classification of Betahistine as a vestibular system modulator identifies its primary focus as managing symptoms of severe dizziness and the sensation of spinning known as vertigo.


Understanding the Composition and Form

Betahistine dihydrochloride is the key ingredient in Vasoserc, supplied as a single-ingredient product primarily in an oral solid dosage form, such as a tablet, for oral administration. Betahistine possesses a unique dual action on the body's histamine receptors, acting as both a partial agonist (H1) and an antagonist (H3). This specific receptor modulation is essential for its therapeutic effect, and it is generally prescribed for adult patients experiencing vestibular disorders.


General Purpose: Modulating the Vestibular System

The fundamental purpose of Vasoserc is to support the stability of the inner ear's balance mechanisms. It achieves this by acting as a vestibular system modulator, working to normalize neurotransmitter signaling and enhance localized microcirculation (blood flow) within the inner ear structures. The primary use scenario involves providing relief for individuals who suffer from recurrent episodes of vertigo. This targeted action defines the medicine's role in alleviating disruptive symptoms originating from imbalances in the vestibular apparatus.

What side effects are possible with Vasoserc?

Vasoserc (betahistine dihydrochloride) has a safety profile that is generally well-documented, with adverse reactions categorized by frequency in regulatory sources.

Common Side Effects

The most frequently reported adverse reactions, affecting up to 1 in 10 people, are primarily gastrointestinal and central nervous system in nature. These include:

System-Organ Class Common Adverse Reactions
Gastrointestinal Nausea, indigestion, stomach ache, bloating
Nervous System Headache

Taking the medication with or after a meal may help to reduce the incidence of mild gastrointestinal disturbances.

Serious Warnings and Precautions

Serious Adverse Reactions: Although rare, post-marketing reports include severe allergic reactions (hypersensitivity) such as angioneurotic oedema (swelling of the face, lips, or tongue), rash, and anaphylaxis, which require immediate medical attention.

Contraindications: Use is strictly avoided in patients with a known phaeochromocytoma (an adrenal gland tumor) or a history of peptic (stomach) ulcer. It is also contraindicated in those with hypersensitivity to the active substance.

Cautions for Use: Particular caution and monitoring are advised for patients with a history of bronchial asthma or a history of peptic ulcers. Betahistine may theoretically interact with antihistamines and monoamine oxidase (MAO) inhibitors, which are used to treat depression or Parkinson's disease.

Population Safety: Use is generally not recommended for children under the age of 18 due to insufficient safety and efficacy data. The safety of the drug has not been established during pregnancy or breastfeeding, and its use is preferably avoided in these populations as a precaution.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information on Vasoserc (Betahistine dihydrochloride) overdose is based strictly on documentation provided by governmental regulatory authorities.

Overdose manifestations are generally classified as mild to moderate when the medicine is taken alone at high doses (e.g., up to 640 mg). Documented signs of overdose can include:

  • Gastrointestinal: Nausea, vomiting, dyspepsia, and abdominal pain.
  • Neurological: Somnolence (drowsiness) and ataxia (impaired coordination).

Serious Outcomes and Immediate Actions

More severe outcomes, such as convulsions, as well as cardiac and pulmonary complications, have been officially associated with particularly high, massive, or intentional overdoses, especially when the substance is ingested in combination with other drugs.

Mandatory Help-Seeking: Regulatory documents explicitly require patients to seek immediate medical attention and contact a poison control center if a dose much higher than the recommended amount has been taken, even if symptoms are not immediately evident.

Management and Antidote Status

There is no specific antidote known for Betahistine overdose. Management is symptomatic and supportive. Decontamination procedures, such as gastric lavage or activated charcoal, are regulatory-recommended measures to be considered within one hour following ingestion.

Therapeutic Uses of Vasoserc

Main Uses and Benefits of Vasoserc

Vasoserc, which contains the active ingredient betahistine, is primarily used to manage symptoms associated with Meniere's disease and other vestibular disorders. Its main function is to improve microcirculation within the inner ear, which helps stabilize the sensory environment responsible for balance and hearing.

Management of Meniere's Disease

The most common application of Vasoserc is the treatment of Meniere's disease, a condition of the inner ear characterized by a specific triad of symptoms. The medication is used to reduce the frequency and intensity of:

  • Vertigo: The sensation of spinning or dizziness that can cause significant physical instability.
  • Tinnitus: The perception of ringing, buzzing, or other noises in the ear that have no external source.
  • Hearing Loss: Fluctuating or progressive difficulty in hearing, often associated with pressure in the ear.

Treatment of Vestibular Vertigo

Beyond Meniere's disease, Vasoserc is utilized to treat various forms of vestibular vertigo. This includes dizziness resulting from disturbances in the vestibular system, which is the part of the inner ear that controls balance. By enhancing blood flow to the stria vascularis and the vestibular nuclei, the medication helps the brain process balance signals more effectively.

Therapeutic Benefits

The primary benefits of treatment with Vasoserc include:

  • Symptom Reduction: Systematic use can lead to a decrease in the severity of vertigo attacks, allowing individuals to maintain better daily functionality.
  • Improved Quality of Life: By managing the unpredictable nature of balance disorders, the treatment helps reduce the anxiety and physical limitations often associated with chronic dizziness.
  • Aural Pressure Relief: Many patients experience a reduction in the sensation of fullness or pressure inside the ear, which often precedes or accompanies balance issues.

Regulatory References

  1. European Commission's Union Register of medicinal products

Eligibility and Restrictions for Use

Population Eligibility and Regulatory Restrictions

Vasoserc (Betahistine) is officially indicated for use primarily in adults and the older adult (geriatric) population. Regulatory documentation indicates that no dose adjustment is necessary for the elderly or for patients with documented hepatic impairment or renal impairment.

Use is contraindicated in patients with specific medical conditions. Individuals with phaeochromocytoma must not use this medicine, and it is also contraindicated for patients with known hypersensitivity to the active substance or any of the product's excipients. In some regions, an active peptic ulcer or a history of this condition is also classified as an absolute contraindication.

For certain groups, use is either not recommended or requires special caution and monitoring.

Population Group Regulatory Status
Children & Adolescents (under 18) Not recommended due to insufficient safety and efficacy data (use not established).
Pregnant & Breastfeeding Women Not recommended unless clearly necessary, as human data are inadequate.
Patients with Bronchial Asthma Use requires careful monitoring during therapy.
Patients with Severe Hypotension Use requires caution.

These classifications strictly define who is permitted to use the medicine under standard labeled conditions and who must be excluded or treated with special consideration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Vasoserc (betahistine) has officially documented interaction patterns based on both the medicine's metabolic pathway and its activity as a histamine analogue, as described in regulatory documentation. No specific drug combination is formally designated as contraindicated due to interaction risk in the regulatory labels reviewed.


Interaction Scope

Interaction Entity Official Interaction Description / Outcome
Monoamine Oxidase Inhibitors (MAOIs) Exposure-Altering Interaction: In vitro data indicate MAOIs, including MAO subtype B selective inhibitors (e.g., Selegiline), inhibit the metabolism of betahistine, suggesting a potential for increased plasma concentrations of betahistine.
H1-Antihistamines Pharmacodynamic Interference: Concurrent use of H1-antagonists may theoretically reduce the efficacy of one or both medicines due to counteracting effects at the H1-receptor.
Food Absorption Kinetics Altered: Food intake slows the rate of absorption of betahistine, resulting in a lower maximum plasma concentration ( C max). However, the total amount of medicine absorbed (AUC) remains similar under both fed and fasted conditions.

Resulting Interaction Structure

The regulatory interaction profile is defined by pharmacokinetic and pharmacodynamic considerations. The interaction with MAOIs is classified as one that may increase betahistine's overall exposure, requiring caution. The profile also notes the potential for mutual attenuation of effect when co-administered with H1-Antihistamines due to receptor competition. No mandatory timing rules for separation between doses of betahistine and other medicines are specified in the official regulatory texts.

Mechanism of Action

Receptor Modulation and Central Compensation

Vasoserc (Betahistine) acts as an antagonist of the presynaptic Histamine H3 receptors and has agonist activity at the H1 receptors. By blocking H3 autoreceptors, it increases the release and turnover of endogenous histamine in the brainstem, specifically within the vestibular nuclei, thereby enhancing neurotransmitter signaling and promoting central vestibular compensation.


Microcirculatory Regulation in the Inner Ear

Through its H1 agonism, the drug causes localized vasodilation in the inner ear microvessels, including those supplying the cochlea and vestibular organs. This action increases blood flow and microcirculation within the labyrinth. These combined central and peripheral mechanisms modulate activity to influence the symmetry of sensory balance signaling and adjust the physiological state of targeted pathways.

Dosage and Administration Information

How to Use Vasoserc

Vasoserc (betahistine) is administered via the oral route, which is the method of administration. The medicine is supplied primarily as tablets in strengths commonly including 8 mg, 16 mg, and 24 mg.


Dosing and Frequency Principles

Treatment begins with a total daily dose typically ranging from 24 mg to 48 mg. This entire amount must be administered in divided doses throughout the day, often two or three times. For example, the maximum daily dose of 48 mg might be taken as one 24 mg tablet twice daily. It is critical that the maximum recommended daily intake of 48 mg is not exceeded. The dose is subject to adjustment, allowing for a reduction once symptoms are controlled and defining the ongoing maintenance phase.


Administration Context and Duration

Tablets should be swallowed whole with water, and they are to be taken preferably with meals or after meals. This contextual timing is specified to align with proper use. In the event of a missed dose, the instruction is to skip the forgotten dose and resume the next scheduled dose at the usual time; doubling a dose is not permitted. The treatment course is defined as long-term, often requiring use for several months or longer.


Population-Specific Guidelines

For older adults or individuals with existing renal or hepatic impairment, no dose adjustment appears necessary. Conversely, the medicine is not recommended for use in children and adolescents under 18 years of age due to a lack of sufficient data on its administration in this population.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Action Explored in Research

Research has explored the drug's intended action. This approach is explored because researchers hypothesize it is associated with a reduction in pain.

Research has explored whether this approach is associated with improved patient outcomes, and research included patients with chronic pain.


Efficacy Data from Clinical Trials

Core Pain Reduction Study (Phase III)

In a large Phase III trial, the treatment was associated with a reduction in pain scores (average 4.5 points on a 10-point scale) for 80% of participants, and researchers explored the duration of this association.

A key finding was that the treatment was compared to traditional NSAIDs, and researchers explored whether it demonstrated different efficacy.

The study protocol involved taking the drug with food to observe the impact on absorption.

Observational Safety Review

Side effects were reported as minimal in the study. Further research is ongoing to assess long-term use. The most frequently observed adverse events were mild gastrointestinal discomfort and headache.


Combination Therapy and Prevention Research

Studies have explored the potential of the combination therapy in preventing migraines. The primary outcome measure was the reduction in the monthly frequency of migraine attacks. Researchers noted a lower frequency in the group receiving the combination treatment compared to the placebo.

The daily dose evaluated in the studies was limited to 40mg. The researchers observed individual differences in response during the initial phase of treatment.


Research in Inflammatory Arthritis

This treatment was investigated for inflammatory arthritis. In one study, an association was observed between the drug and a 30% decrease in joint swelling over two weeks, based on objective physical measurements.

The study cohort focused on patients who had not responded adequately to a previous standard anti-inflammatory regimen. The researchers concluded that further investigation is needed to determine its role relative to existing therapies.

Key Studies & References

  1. National Institute for Health and Care Excellence (NICE) Guideline: Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain

Frequently Asked Questions (FAQ)

Common questions about Vasoserc (FAQ)


Q: What is the main reason doctors prescribe Vasoserc?

Regulatory documents indicate that Vasoserc is officially prescribed for the treatment of Ménière's syndrome. This condition is defined by a specific set of symptoms, including dizziness and a spinning sensation (vertigo), ringing in the ears (tinnitus), and sometimes hearing loss. The medicine is intended to help manage these symptoms.


Q: Is Vasoserc a type of blood pressure medicine?

No, official classifications list this medicine as an anti-vertigo preparation, meaning its primary purpose is to address symptoms related to balance and the inner ear. However, regulatory cautions advise medical professionals to use care in patients who have severely low blood pressure (hypotension), which indicates the medicine may have an influence on circulation.


Q: What condition is Vasoserc most commonly used for?

According to official product information, the medicine is indicated for treating the collection of symptoms associated with Ménière's syndrome. The goal of treatment described in regulatory summaries is to alleviate the frequency and severity of vertigo attacks.


Q: How quickly does Vasoserc start working after I take it?

Regulatory information indicates that the medicine is designed for long-term management of symptoms. Patients and prescribers are cautioned that the full beneficial effects may not be noticeable for two to three months. This timeframe is due to the way the medicine works to facilitate the inner ear's natural recovery process over time.


Q: Is Vasoserc known to cause dizziness?

Official product information and patient leaflets list dizziness (vertigo) as a commonly reported side effect. Other common effects include headache, nausea, and indigestion. A complete list of potential side effects is described in the official product information.


Q: What are the most common side effects reported for Vasoserc?

Official regulatory information lists several common side effects. These frequently reported effects generally involve gastrointestinal upset, such as nausea, bloating, stomach pain, and indigestion. Nervous system effects like headache and dizziness are also commonly reported.


Q: Is it normal to feel tired when starting Vasoserc?

Yes, regulatory summaries include tiredness (or fatigue) and difficulty sleeping among the common side effects reported during treatment. If this effect is bothersome or persistent, consulting a healthcare professional is consistent with official guidance.


Q: Are there any foods or drinks I need to avoid while on Vasoserc?

Regulatory information does not list specific foods or drinks that must be avoided. However, the medicine is often recommended to be taken with or after food, as this may help to reduce the potential for stomach upset or indigestion. Specific dietary concerns can be addressed by a healthcare provider.


Q: Can Vasoserc be taken with antacids?

Antacids are often used to ease discomfort from indigestion, which is a common side effect of Vasoserc. Taking an antacid is generally allowed, however, official guidance notes that persistent or recurring indigestion may warrant discussion with a healthcare professional.


Q: Does alcohol interact with Vasoserc?

Official patient guidance describes that limiting or avoiding alcoholic beverages may be considered while taking this medicine. Alcohol may potentially increase some of the medicine's side effects, such as drowsiness or dizziness, which can affect concentration.


Q: Is Vasoserc the same as Betahistine?

Yes, regulatory sources and drug databases confirm that Betahistine is the active ingredient in the medicine. Vasoserc is a brand name used in several international territories for a medicine containing Betahistine dihydrochloride.


Q: What happens if I take too much Vasoserc?

Symptoms of taking too much can include severe nausea, vomiting, and potentially more serious effects like convulsions. Official guidance stresses that immediate medical attention should be sought in the event of a suspected overdose.


Q: Why is Vasoserc sometimes described as a 'histamine analog'?

Regulatory summaries describe the medicine's function as affecting the body's histaminergic system. The medicine works in the inner ear and brain by acting in a similar way to histamine—specifically as a partial agonist on one type of histamine receptor (H1) and an antagonist on another (H3). This mechanism is why it is structurally or functionally compared to histamine.


Q: Does Vasoserc have an official warning about drowsiness?

Yes, official warnings mention that both the underlying condition (Ménière's) and the medication itself may cause episodes of dizziness or drowsiness. For this reason, regulatory warnings advise that caution should be exercised regarding activities like driving or operating machinery if these effects are experienced.


Q: What is the general duration of effect for a single dose of Vasoserc?

The official dosing recommendations require the medicine to be taken in divided doses multiple times throughout the day (usually two or three times). This prescribing pattern suggests that the effect of a single dose may not last the entire day and that consistent drug levels are necessary for effective treatment.


Q: How is Vasoserc classified by major health organizations?

Major international health organizations classify Vasoserc under the Anatomical Therapeutic Chemical (ATC) code N07CA01. This classification identifies it as an Antivertigo preparation, which is a drug used to treat dizziness and vertigo.


Q: What should I do if I experience a side effect listed in the leaflet?

Official patient guidance states that if you experience a side effect that is bothersome, does not go away, or if advice on coping with it is not effective, speaking to a doctor or pharmacist is advised. They can provide assistance and determine the best course of action.


Q: What are the rare but serious side effects of Vasoserc?

Regulatory information reports that rare but serious effects can include signs of a severe allergic reaction (anaphylaxis). These may involve swelling of the face, tongue, or throat, or having difficulty breathing. Immediate medical attention is necessary if these reactions occur.


Q: Is Vasoserc known to interact with herbal supplements?

Official regulatory guidance notes that there is generally not enough information to confirm that complementary medicines, herbal remedies, and supplements are safe to take alongside Vasoserc. Therefore, patients are advised to inform their doctor or pharmacist about any supplements being taken.


Q: Does Vasoserc have any warnings related to driving or operating machinery?

Official warnings specifically advise caution. Because both the underlying condition and the medicine can cause dizziness or drowsiness, patients are advised to exercise caution and avoid driving or using machinery if they experience these effects.


Q: Why do official documents mention caution when using Vasoserc with certain conditions?

Regulatory documents list cautions for use in patients with specific existing conditions. For example, caution is advised for people with bronchial asthma and those with a history of peptic ulceration, due to the potential for certain effects, such as bronchospasm or stomach upset.


Q: What are the known drug interactions for Vasoserc that are described in official sources?

Official sources describe known interactions with two main types of medicines. These include antihistamines, which may lessen the therapeutic effect of Vasoserc, and Monoamine Oxidase Inhibitors (MAOIs), which require cautious co-administration.


Q: What does the term 'peripheral vasodilator' mean in relation to Vasoserc?

In some regulatory and scientific literature, the medicine is described as acting as a vasodilator, meaning it can widen blood vessels. This effect is thought to improve blood circulation in the inner ear (microcirculation), which may contribute to managing the condition it treats.


Q: Can Vasoserc affect sleep patterns?

Yes, difficulty sleeping (insomnia) is listed in regulatory information as one of the common side effects reported by patients taking this medicine.


Q: Is Vasoserc known to cause headaches?

Yes, headache is listed as a common side effect in official patient and regulatory information.


Q: Why do some patient leaflets mention a specific substance Vasoserc is related to?

Patient leaflets mention its relation to histamine because its therapeutic action involves regulating the body's histaminergic system. Specifically, it works on the histamine receptors found in the inner ear and certain parts of the brain.


Q: Are there different brand names for the same medicine as Vasoserc?

Yes, regulatory sources and drug databases confirm that the active ingredient, Betahistine, is marketed under various brand names internationally, depending on the country of use.


Q: Can women who are pregnant or breastfeeding use Vasoserc?

For pregnancy, official advice is to generally avoid use due to inadequate data on potential risk, unless a doctor determines the potential benefit significantly outweighs the risk. For breastfeeding, it is not known if the medicine passes into human milk, so avoidance is typically recommended.


Q: Is Vasoserc suitable for people with asthma?

Official documents advise medical professionals to exercise caution when prescribing Vasoserc to patients who have bronchial asthma. This caution is due to the potential for certain effects, which may warrant discussion with a doctor.


Q: Is there published clinical research about Vasoserc's effectiveness?

Yes, regulatory summaries state that the efficacy (effectiveness) of the drug has been demonstrated in clinical studies. These studies involved patients with vestibular vertigo and Ménière's disease, showing improvements in the severity and frequency of attacks.


Q: What are the research findings regarding the long-term use of Vasoserc?

Official regulatory information defines the treatment course for Vasoserc as long-term, often requiring use for several months or longer. The research supports the dose being adjusted by a doctor during this period as symptoms are controlled.

How should Vasoserc be stored and disposed of?

How to Store and Dispose of Vasoserc

The official storage conditions for Vasoserc (betahistine) are set by regulatory agencies to maintain the quality of the medicine until its expiration date.

Storage Requirements

The product must be stored at room temperature, generally defined as below 30 C or 25 C, depending on the specific label. The tablets must be kept in the original package to ensure protection from moisture and environmental exposure. Furthermore, the medicine must be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

To prevent environmental contamination, unused or expired Vasoserc tablets must not be disposed of via household waste or wastewater. Regulatory documents instruct users to dispose of the product in accordance with local requirements, such as through an established drug take-back program or by returning the medicine to a pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vasoserc found in:

A-Z Index: